Lung transplant recipients

Iacono AT, Johnson BA, Grgurich WF, Yossef JG, et al. 2006. A randomized trial of inhaled cyclosporine in lung-transplant recipients. 354 141-150. 

Lau CL, Palmer SM, Posther KE, Howell DN, et al. 2000. Influence of panel-reactive antibodies on post transplant outcomes in lung transplant recipients. Ann Thorac Surg. 69 1520-1524. 

Vaughn BV, Ali II, Olivier KN, Lackner RP, Robertson KR, Messenheimer JA, Paradowski LJ, Egan TM. Seizures in 64. lung transplant recipients. Epilepsia 1996 37(12) 1175-9. 

Gross C, Savik K, Bolman RM, Hertz MI. Long-term health status and quality of life outcomes of lung transplant recipients. Chest 1995 108 1587-1593. 

Hulten LM, Lindmark H, Schersten H, Wiklund O, Nilsson FN and Riise GC. Butylated hydroxytoluene and N-acetylcysteine attenuates tumor necrosis factor-alpha (TNF-alpha) secretion and TNF-alpha mRNA expression in alveolar macrophages from human lung transplant recipients in vitro. Transplantation 6(2). 364-369, 1998. 

Continuous infusion of amphotericin has been assessed in an open study in six lung transplant recipients with invasive or semi-invasive bronchopulmonary azole-resistant candidal infections who were treated for 40 (17-73) days by 24-hour continuous infusions of amphotericin 1 mg/kg (113). They received at least 1000 ml/day of 0.9% saline intravenously. Apart from ciclosporin, five patients received aminoglycosides for at least 2 weeks, and four received ganciclovir. Calculated creatinine clearance fell from 57 (43-73) ml/minute to a nadir of 35 (28-39) and recovered to 52 (33-60) after the end of therapy. One patient needed temporary hemofiltration for 7 days. Besides three episodes of mild hypokalemia there were no adverse effects attributable to amphotericin. Asymptomatic colonization with Candida persisted for 10 months in one case, but the other five patients were cured. 

Pahner SM, Drew RH, Whitehouse JD, Tapson VF, Davis RD, McConnell RR, Kanj SS, Perfect JR. Safety of aerosolized amphotericin B hpid complex in lung transplant recipients. Transplantation 2001 72(3) 545-8. 

Speich R, Dntly A, Naef R, Russi EW, Weder W, Boehler A. Tolerability, safety and efficacy of conventional amphotericin B administered by 24-honr infusion to lung transplant recipients. Swiss Med Wkly 2002 132(31-32) 455-8. 

Jahansouz F, Kriett JM, Smith CM, Jamieson SW. Potentiation of cyclosporine nephrotoxicity by nafcillin in lung transplant recipients. Transplantation... 

Kilpatrick NM, Weintraub RG, Lucas JO, Shipp A, Byrt T, Wilkinson JL. Gingival overgrowth in pediatric heart and heart-lung transplant recipients. J Heart Lung Transplant 1997 16(12) 1231-7. 

Ciprofloxacin can be associated with partial or complete tendinitis. Of 72 lung transplant recipients who received ciprofloxacin, 20 had Achilles tendon involvement (tendinitis 15, rupture 5) (49). Tendon rupture occurred at a lower dosage of ciprofloxacin than tendinitis and the mean recovery duration was significantly longer. 

Chhajed PN, Plit ML, Hopkins PM, Malouf MA, Glanville AR. Achilles tendon disease in lung transplant recipients association with ciprofloxacin. Eur Respir J 2002 19(3) 469-71. 

Theodore J. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990 113(4) 327-9. 

Furlan V, Parquin F, Penaud JF, Cerrina J, Ladurie FL, Dartevelle P, Taburet AM. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. Transplant Proc 1998 30(l) 187-8. 

In a study in lung transplant recipients, ciclosporin nephrotoxicity was potentiated by nafcillin (111). 

Chan C, Maurer J, Cardella C, Cattran D, Pei Y. A randomized controlled trial of verapamil on cyclosporine nephrotoxicity in heart and lung transplant recipients.Transplantation 1997 63 1435-1440. 

Pattison JM, Petersen J, Kuo P, Valantine V, Robbins RC,Theodore J.The incidence of renal failure in one hundred consecutive heart-lung transplant recipients. Am J Kidney Dis 1995 26 643-648. 

Zaltzman JS, Pei Y, Maurer J, Patterson A, Cattran DC. Cyclosporine nephrotoxicity in lung transplant recipients.Transplantation... 

Tirdel et al. [118] researched metabolic myopathy as a cause of the exercise limitation in lung transplant recipients, while Noriyuki et al. [119] evaluated lung tissue oxygenation using NIR spectroscopy. 

G. B. Tirdel, R. Girgis, R. S. Fishman, and J. Theodore, Metabolic Myopathy as a Cause of the Exercise Limitation in Lung Transplant Recipients, J. Heart Lung Transpl., 17(12), 1231-1237 (1998). 

The most severe CMV infections are seen in those individuals who acquire their primary infection while immunocompromised. In persons with AIDS, CMV disease rarely occurs when the CD4+ cell count is above 100 cells/mm the most common clinical presentations are retinitis, esophagitis, and colitis. In transplant recipients, the occurrence and severity of CMV disease are related to the CMV serostatus of the organ donor and recipient, the type of organ transplanted, and the overall degree of immunosuppression. For example, CMV disease tends to be more severe in lung transplant recipients than in renal transplant recipients. For aU types of organ recipients, the most severe disease occurs... 

Reams BD, Davis RD, Curl J, Palmer SM. Treatment of refractory acute rejection in a lung transplant recipient with campath IH. Transplanation 2002 74 903. 

Solans EP, Yong S, Husain AN, et al. Bronchioloalveolar lavage in the diagnosis of CMV pneumonitis in lung transplant recipients an immunocytochemical study. Diagn Cytopath. 1997 16 350-352. 

Simsir A, Greenebaum E, Nuovo G, et al. Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation. 1998 65 592-594. 

Ohori NP, Michaels MG, Jaffe R, et al. Adenovirus pneumonia in lung transplant recipients. Hum Pathol. 1995 26 1073-1079. 

Zhao W, Martin AD, Davenport PW (2002) Respiratory-related evoked potentials elicited by inspiratory occlusions in double-lung transplant recipients. J Appl Physiol 93(3) 894-902... 

Shennib H, Auger J-L. Diltiazem improves cyclotorine dosage in C3rstic fibrosis lung transplant recipients. Transplant 13, 292-6. 

Tsang VT, Johnston A, Heritier F, Leaver N, HodsonME, YacoubM Cyclosporin pharmacokinetics in heart-lung transplant recipients with cystic fibrosis. Fur J CUn Pharmacol (1994) 46, 261-5. 

Dosanjh AK, Elashoff D, Robbins RC. The bronchoalveolar lavage fluid of cystic fibrosis lung transplant recipients demonstrates increased interleukin-8 and elastase and decreased IL-10. J Interferon Cytokine Res 1998 18 851. 

---